Aduhelm, a new therapy from Biogen, is the first drug to target Alzheimer’s disease in nearly 20 years, and will have cascading effects on health care costs.
Related posts:
CDC chief warns of ‘impending doom’ as Covid cases surge
In Mississippi and New York City, leaders fight to overcome vaccine obstacles
‘A tough call’: Biden considering mandatory Covid vaccines for U.S. troops
States won’t get Johnson & Johnson vaccines next week
Poll: Slim majority in U.S. backs return of masking
Drug industry banks on its Covid clout to halt Dems’ push on prices
The political fallout of Texas’ abortion ban
‘It’s a sore spot for a lot of people’: Why officials are raising questions about Biden’s vaccine donations
Texas, Florida see uptick in Obamacare enrollment
Pfizer’s Covid-19 pill cut risk of hospitalization and death by 89 percent, final results show
Senate panel advances Biden’s FDA pick in 13-8 vote
Beijing to offer Olympic tickets to ‘selected’ spectators amid pandemic
